Is ABT stock a Buy, Sell, or Hold?

Based on our analysis, ABT is currently a WAIT with low confidence. 📊 MIXED SIGNALS: ABT shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of ABT stock?

Our analysis estimates the fair value range for ABT to be between $98.18 and $111.10. The current price is $114.43.

What is the analyst price target for ABT?

The average Wall Street analyst price target for ABT is $119.40. This implies a potential upside of 4.3% from current levels.

ABT Stock Analysis: Buy, Sell, or Hold?

ABT - Abbott Laboratories

PHARMACEUTICAL PREPARATIONS

$114.43

1.75 (1.55%) ▲

5d: +3.17%

30d: +14.81%

90d: +28.83%

WAIT

LOW Confidence

Protect Your ABT Gains

Analysis Updated: Aug 19, 2026 12:00 AM ET

Earnings: Oct 14, 2026

Smart Money Distribution

Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →

Signal fired Aug 10, 2026 at $108.62 · last confirmed Aug 18, 2026

Strength: 5.7/10

Get Alerted When ABT Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: ABT shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 9.9%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$147.50

Based on 7.0% avg growth

INTRINSIC VALUE TODAY

$91.58

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.4x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: ABT is currently trading at $114.43, which is considered extended relative to its 30-day fair value range of $98.18 to $111.10. The stock's valuation (Forward PE: 18.9) is in line with its historical norms (17.4). At these levels, the market is pricing in 2.6% annual earnings growth.

Technical Outlook: Technically, ABT is in a uptrend. The price is approaching resistance at $115.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: ABT scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED

Historical Trading Range $98.18 - $111.10

Company Quality Score 38/100 (SELL)

Volume Confirmation HIGH

Confidence Score 27.1%

Protect Your Profits

ABT is technically overbought (RSI 76). Consider hedging now to protect against a potential pullback while keeping your upside.

View Profit Protection Plan

All Signals

BEARISH: Price extended above range
BEARISH: Weak technical setup (25/100)
BULLISH: High volume confirmation
NEUTRAL: Near Wall St target ($119.40)
BULLISH: Expecting earnings turnaround to 2.6% growth with 13.0% revenue growth
WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $98.18 - $111.10

Current vs Trading Range EXTENDED

Support & Resistance Levels

Support Level $105.56

Resistance Level $115.67

Current Trend Uptrend

Technical data as of Aug 19, 2026

Fundamental Context

Forward P/E (Next Year Est.) 18.87

Wall Street Target $119.40 (+4.3%)

Revenue Growth (YoY) 13.0%

Earnings Growth (YoY) -47.5%

Profit Margin 11.7%

Valuation Premium vs History +2.6% premium

PE vs Historical 18.9 vs 17.4 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +2.6% (market-implied from PE analysis)

1-Year Target $117.41 (+3%)

2-Year Target $120.46 (+5%)

3-Year Target $123.59 (+8%)

3-Yr Target (if PE normalizes) (PE: 19→17) PE COMPRESSION $113.95 (0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 20.1, Growth: 9.9%) $161.48 (+41%)

Base: (SPY PE: 18.9, Growth: 9.9%) $151.84 (+33%)

Bear: (PE: 16.0, Growth: 9.9%) $129.06 (+13%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (36x PE), but valuation improves significantly next year (19x PE) as earnings recover.

Trailing PE: 35.66 | Current EPS (TTM): $3.16

Bull Case $237.84 (+108%)

Analyst growth 91.9%, PE expands to 39.2

Base Case $216.22 (+89%)

Market implied 91.9%, PE stable at 35.7

Bear Case $76.62 (-33%)

Severe decline -20.0%, PE contracts to 30.3

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: August 20, 2026 2:58 AM ET
Data refreshes hourly during market hours. Next update: 3:58 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is ABT showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Ro Khanna SELL 2026-03-30

Laura Friedman SELL 2026-03-24

Ro Khanna BUY 2026-03-23

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for ABT.

Create Free Account

Already have an account? Log In

Featured in Portfolios

ABT is a key holding in these high-performance investment strategies.

Dividend Aristocrats Income • +16.3% Return

View All Strategies

Top Rated Medical Devices Stocks

Top-rated stocks in Medical Devices by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
BSX Boston Scientific Corp	STRONG BUY 34 analysts	$63	39 SELL
SYK Stryker Corporation	BUY 32 analysts	$383	56 HOLD
MDT Medtronic PLC	BUY 32 analysts	$98	50 HOLD
PODD Insulet Corporation	STRONG BUY 24 analysts	$172	45 HOLD
GEHC GE HealthCare Technologi…	STRONG BUY 21 analysts	$83	37 SELL

BSX Boston Scientific…

39 SELL

SYK Stryker Corporati…

56 HOLD

MDT Medtronic PLC

50 HOLD

PODD Insulet Corporati…

45 HOLD

GEHC GE HealthCare Tec…

37 SELL

Advanced ABT Option Strategies

Professional options setups generated by AI based on today's ABT price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ABT

ABT Technical Chart ABT Price Prediction ABT Earnings Date ABT Investment Advisor ABT Fair Price Analyzer ABT Options Advisor ABT Options Chain ABT Options Analysis ABT Competitors

Compare ABT with Peers

ABT vs ABBV
Which one to buy?

ABT vs BMY
Which one to buy?

ABT vs JNJ
Which one to buy?

ABT vs MDT
Which one to buy?

ABT vs LLY
Which one to buy?

MURA vs ABT

CVS vs ABT
Winner: CVS

Create New Comparison View All Competitors

Tradestie